Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Glythera Ltd.
DescriptionCysteine-specific, highly stable linker designs for conjugation of various cargos to proteins and peptides
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today